Amgen (AMGN) Wins Otezla Patent Case
- World stocks hold near 6-week highs in big earnings week
- Tesla (TSLA): New Price Target of $1,200 Implies HALF the Company's Growth Target - Morgan Stanley
- PayPal (PYPL) Stock Soars Over 6% on Confirmation It Won't Acquire Pinterest (PINS) 'At This Time'; PINS Stock Down 11%
- Oil prices extend gains to multi-year highs on tight supply
- Tesla (TSLA) Model S and Model X Prices Raised by $5,000
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
Amgen today announced that the U.S. District Court for the District of New Jersey has upheld patents that protect Amgen's (NASDAQ: AMGN) psoriasis therapy Otezla® (apremilast) in a patent infringement lawsuit against Sandoz Inc. ("Sandoz") and Zydus Pharmaceuticals (USA), Inc. ("Zydus"). The asserted patents claim apremilast as a composition of matter ("COM"), methods of treating psoriasis with apremilast, and crystalline forms of apremilast. The court found infringement and upheld the validity of four patents – three against each defendant -- but ruled against Amgen on claims in U.S. Patent No. 10,092,541 covering methods of treating psoriasis with apremilast according to a specific dosing schedule. Today's decision will prevent Sandoz and Zydus from making, using, selling, offering to sell, or importing each of their generic versions of Otezla until expiration of the COM patent, U.S. Patent No. 7,427,638, in Feb. 2028.
The decision comes after the New Jersey court held a bench trial in June 2021. Prior to trial, Sandoz acknowledged that its generic version of Otezla infringes eight claims in U.S. Patent Nos. 7,427,638, 7,893,101, 8,455,536, and 10,092,541, and Zydus acknowledged that its generic version of Otezla infringes eight claims in U.S. Patent Nos. 7,427,638, 8,093,283, 8,455,536, and 10,092,541, leaving only the issues of whether Zydus's generic version of Otezla infringes U.S. Patent No. 7,893,101 and the validity of the asserted patent claims to be addressed by the court.
Amgen believes in the value of intellectual property and will continue to vigorously defend its intellectual property rights.
In the U.S., Otezla is approved for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic therapy, adult patients with active psoriatic arthritis and adult patients with oral ulcers associated with Behçet's Disease.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Redhill Biopharma Ltd (REDIF) Reports New Talicia and Movantik Data Analyses
- AstraZeneca (AZN) Reports Positive Interim Data From TOPAZ-1 Phase III Trial
- Amgen (AMGN) Declares $1.76 Quarterly Dividend; 3.4% Yield
Create E-mail Alert Related CategoriesCorporate News, FDA
Related EntitiesTwitter, Dividend, Definitive Agreement
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!